The Interleukin 13 Receptor pipeline drugs market research report outlays comprehensive information on the Interleukin 13 Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 13 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Undisclosed, Dermatology, and Toxicology which include the indications Glioblastoma Multiforme (GBM), Recurrent Glioblastoma Multiforme (GBM), Unspecified, Atopic Dermatitis (Atopic Eczema), and Chemotherapy Induced Peripheral Neuropathy. It also reviews key players involved in Interleukin 13 Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Interleukin 13 Receptor pipeline targets constitutes close to 48 molecules. Out of which, approximately 43 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 8, 1, 23, and 8 respectively. Similarly, the universities portfolio in Phase I, and Preclinical comprises 2, and 3 molecule.
Interleukin 13 Receptor overview
Interleukin 13 Receptor (IL13R) is a type I cytokine receptor, binding Interleukin-13. It composed of two subunits, encoded by IL13RA1 and IL4R. These two genes encode the proteins IL-13Rα1 and IL-4Rα. These form a dimer with IL-13 binding to the IL-13Rα1 chain and IL-4Rα stabilises this interaction.
For a complete picture of Interleukin 13 Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
